Company intelligence / Profile preview

CambriaTech Holding

Baar, Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

CambriaTech Holding was a biotechnology holding company that operated primarily through its subsidiary, Cambria Pharmaceuticals. The company focused on discovering small molecule drugs for neurodegenerative diseases, with a particular emphasis on Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Its core technology utilized a proprietary yeast-based screening platform to identify compounds that stabilize proteins prone to misfolding, such as SOD1. In 2011, the company entered into a major strategic collaboration with Biogen Idec to develop its SOD1 stabilizer program for ALS. Despite its innovative approach to protein aggregation, the company has since ceased active operations and entered liquidation.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Biogen

Beyond the preview

Go deeper on CambriaTech Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CambriaTech Holding.

Explore the full profile